Aignostics plans to utilize the new $34M funding to enhance target identification, translational research, and diagnostic applications, expanding its product offerings significantly.
CEO Viktor Matyas stated that 2024 has been pivotal for Aignostics with strategic collaborations and innovations like their foundation model, RudolfV, aiming for integral AI solutions.
#ai-in-healthcare #series-b-funding #pathology-insights #precision-medicine #biopharmaceutical-collaboration
Collection
[
|
...
]